Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C

Background: The World Health Organization (WHO) has identified the need for a better understanding of which patients with hepatitis C virus (HCV) can be cured with ultrashort course HCV therapy. Methods: A total of 202 individuals with chronic HCV were randomised to fixed-duration shortened therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooke, Graham S., Pett, Sarah, McCabe, Leanne, Jones, Chris, Gilson, Richard, Verma, Sumita, Ryder, Stephen D., Collier, Jane D., Barclay, Stephen T., Ala, Aftab, Bhagani, Sanjay, Nelson, Mark, Ch'Ng, Chinlye, Stone, Ben, Wiselka, Martin, Forton, Daniel, McPherson, Stuart, Halford, Rachel, Nguyen, Dung, Smith, David, Ansari, Azim, Dennis, Emily, Hudson, Fleur, Barnes, Eleanor J., Walker, Ann Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361811/
https://www.ncbi.nlm.nih.gov/pubmed/34405118
http://dx.doi.org/10.12688/wellcomeopenres.16594.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361811/
https://www.ncbi.nlm.nih.gov/pubmed/34405118
http://dx.doi.org/10.12688/wellcomeopenres.16594.2

Ejemplares similares